Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for LEGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 96.16M
March 31, 2026 85.96M
December 31, 2025 101.77M
September 30, 2025 113.30M
June 30, 2025 98.65M
March 31, 2025 101.92M
December 31, 2024 104.06M
September 30, 2024 95.52M
June 30, 2024 112.63M
March 31, 2024 100.96M
December 31, 2023 105.68M
September 30, 2023 95.86M
June 30, 2023 95.79M
March 31, 2023 84.89M
Date Value
December 31, 2022 80.76M
September 30, 2022 104.52M
June 30, 2022 68.83M
March 31, 2022 81.55M
December 31, 2021 86.50M
September 30, 2021 72.31M
June 30, 2021 83.46M
March 31, 2021 70.93M
December 31, 2020 67.14M
September 30, 2020 63.66M
June 30, 2020 53.57M
March 31, 2020 48.00M
December 31, 2019 66.10M
September 30, 2019 41.92M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Dianthus Therapeutics, Inc. 48.69M
Gilead Sciences, Inc. 1.69B
Ironwood Pharmaceuticals, Inc. 21.96M
Arbutus Biopharma Corp. 2.898M
Fortress Biotech, Inc. 0.805M